Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$806M |
| 2 |
AbbVie
ABBV
|
+$481M |
| 3 |
T-Mobile US
TMUS
|
+$464M |
| 4 |
Kroger
KR
|
+$430M |
| 5 |
Baidu
BIDU
|
+$423M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.35B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
S
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$488M |
| 5 |
Humana
HUM
|
+$450M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.76% |
| 2 | Technology | 16.41% |
| 3 | Consumer Staples | 10.58% |
| 4 | Consumer Discretionary | 10.12% |
| 5 | Communication Services | 9.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3151
Citizens Community Bancorp
CZWI
$204M
| $205K | ﹤0.01% |
29,900
+15,426
| +107% | +$108K |
2016 Q3
15 quarters
|
|
3152
iShares 5-10 Year Investment Grade Corporate Bond ETF
IGIB
$18.7B
| $205K | ﹤0.01% |
+3,400
| New | +$198K |
2020 Q2
0 quarters
|
|
|
MNK
3153
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $205K | ﹤0.01% |
+76,600
| New | +$230K |
2020 Q2
0 quarters
|
|
3154
ProShares UltraShort MSCI Brazil Capped
BZQ
$1.85M
| $204K | ﹤0.01% |
+731
| New | +$301K |
2020 Q2
0 quarters
|
|
|
CNTG
3155
DELISTED
Centogene N.V. Common Shares
CNTG
| $204K | ﹤0.01% |
+8,900
| New | +$167K |
2020 Q2
0 quarters
|
|
3156
Cibus
CBUS
$118M
| $202K | ﹤0.01% |
818
-244
| -23% | -$54.6K |
2019 Q3
3 quarters
|
|
3157
Xtant Medical Holdings
XTNT
$45.7M
| $202K | ﹤0.01% |
224,688
+135,927
| +153% | +$125K |
2017 Q3
11 quarters
|
|
|
CKPT
3158
DELISTED
Checkpoint Therapeutics
CKPT
| $201K | ﹤0.01% |
10,150
+5,560
| +121% | +$101K |
2018 Q3
7 quarters
|
|
3159
iShares MSCI KLD 400 Social ETF
DSI
$5.58B
| $201K | ﹤0.01% |
+3,400
| New | +$189K |
2020 Q2
0 quarters
|
|
|
LFT
3160
Lument Finance Trust
LFT
$27.2M
| $201K | ﹤0.01% |
7,571
-2,900
| -28% | -$63.2K |
2019 Q4
2 quarters
|
|
3161
Nortech Systems
NSYS
$32.4M
| $201K | ﹤0.01% |
46,959
-6,580
| -12% | -$24.6K |
2015 Q1
21 quarters
|
|
|
RGLS
3162
DELISTED
Regulus Therapeutics
RGLS
| $201K | ﹤0.01% |
29,526
-22,122
| -43% | -$145K |
2017 Q3
11 quarters
|
|
3163
Farmmi Inc
FAMI
$4.61M
| $200K | ﹤0.01% |
119
+56
| +89% | +$75.1K |
2019 Q4
2 quarters
|
|
3164
Dana Inc
DAN
$3.16B
| $199K | ﹤0.01% |
+16,292
| New | +$177K |
2020 Q2
0 quarters
|
|
3165
Achieve Life Sciences
ACHV
$764M
| $198K | ﹤0.01% |
24,962
-10,693
| -30% | -$85.2K |
2013 Q2
28 quarters
|
|
|
MNTX
3166
DELISTED
Manitex International, Inc.
MNTX
| $198K | ﹤0.01% |
39,840
+2,700
| +7% | +$11.5K |
2019 Q2
4 quarters
|
|
3167
Air Industries Group
AIRI
$13.1M
| $197K | ﹤0.01% |
16,560
-10,670
| -39% | -$120K |
2019 Q4
2 quarters
|
|
|
GES
3168
DELISTED
Guess Inc
GES
| $196K | ﹤0.01% |
20,309
-997,491
| -98% | -$8.77M |
2020 Q1
1 quarter
|
|
3169
Vista Gold
VGZ
$387M
| $196K | ﹤0.01% |
233,800
+143,874
| +160% | +$113K |
2019 Q3
3 quarters
|
|
|
APEX
3170
DELISTED
Apex Global Brands Inc. Common Stock
APEX
| $196K | ﹤0.01% |
17,466
+3,760
| +27% | +$21.2K |
2013 Q2
28 quarters
|
|
3171
Barnwell Industries
BRN
$14.1M
| $195K | ﹤0.01% |
217,344
+55,200
| +34% | +$36.6K |
2013 Q2
28 quarters
|
|
|
ONCT
3172
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
| $193K | ﹤0.01% |
3,402
+2,036
| +149% | +$115K |
2019 Q4
2 quarters
|
|
|
DMTK
3173
DELISTED
DermTech, Inc. Common Stock
DMTK
| $191K | ﹤0.01% |
+14,400
| New | +$188K |
2020 Q2
0 quarters
|
|
3174
IT Tech Packaging
ITP
$2.58M
| $190K | ﹤0.01% |
31,406
+20,036
| +176% | +$115K |
2013 Q2
28 quarters
|
|
3175
Oak Valley Bancorp
OVLY
$281M
| $189K | ﹤0.01% |
14,873
+1,700
| +13% | +$22.7K |
2019 Q4
2 quarters
|
|
Similar funds
Renaissance Technologies's Q2 2020 Portfolio in Review
As of Q2 2020, Renaissance Technologies held 3,987 positions worth $116B, up 13% from $103B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Renaissance Technologies withdrew a net $8.24B in Q2 2020, closing 596 positions and reducing 1,365 holdings. Its most notable exit was Allergan plc, an estimated $1.26B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 26% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Renaissance Technologies opened a new position in Uber worth $187M.
- Renaissance Technologies's largest Q2 2020 buy was Uber: 6,030,316 shares worth $187M.
- Renaissance Technologies added most to Zoom in Q2 2020, an estimated $806M increase.
- Renaissance Technologies's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.35B.
- Renaissance Technologies fully exited Allergan plc in Q2 2020, selling an estimated $1.26B.
- Renaissance Technologies's ten largest holdings make up 14% of its $116B portfolio in Q2 2020.
- Renaissance Technologies opened 584 new positions and closed 596 in Q2 2020.
- Renaissance Technologies's portfolio value rose 13% quarter-over-quarter to $116B.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.